Featured
-
-
Perspective
| Open AccessAspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
- Peter Elwood
- , Gareth Morgan
- & Marcus Longley
-
Article
| Open AccessAssociation between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
- E. Lin
- , Hans Garmo
- & Danielle Crawley
-
Article
| Open AccessAndrogen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer
- Anna R. Michmerhuizen
- , Lynn M. Lerner
- & Corey W. Speers
-
Article |
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
- Elena Élez
- , María Auxiliadora Gómez-España
- & Enrique Aranda
-
Article |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
- Yung-Yeh Su
- , Yen-Feng Chiu
- & Li-Tzong Chen
-
Article |
Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma
- Sarah Bouchereau
- , Louise Chaplain
- & Elisa Funck-Brentano
-
Article
| Open AccessNew clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer
- Jayant S. Vaidya
- , Max Bulsara
- & Jeffrey S. Tobias
-
Article
| Open AccessRandomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
- Baek-Yeol Ryoo
- , Ann-Li Cheng
- & Shukui Qin
-
Article
| Open AccessPhase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression
- Thomas Decaens
- , Carlo Barone
- & Sandrine Faivre
-
Article |
The added value of H2 antagonists in premedication regimens during paclitaxel treatment
- Juul M. Cox
- , Leni van Doorn
- & Roelof W. F. van Leeuwen
-
Comment
| Open AccessSingle-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment
- Jayant S. Vaidya
- , Max Bulsara
- & David J. Joseph
-
Article
| Open AccessIntra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study
- Simon Pernot
- , Olivier Pellerin
- & Julien Taieb
-
Article
| Open AccessCovariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma
- Andrew Briggs
- , Bruno Daniele
- & Gabriel Tremblay
-
Review Article
| Open AccessThe arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
- Liese Barbier
- , Paul Declerck
- & Isabelle Huys
-
Article
| Open AccessRRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer
- Daniel Morgensztern
- , Michal Rose
- & Sukhmani K. Padda
-
Brief Communication
| Open AccessOestradiol measurement during fulvestrant treatment for breast cancer
- Laura J. Owen
- , Phillip J. Monaghan
- & Sacha Howell
-
Consensus Statement
| Open AccessDevelopment of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK
- Robert A. Watson
- , Hugo De La Peña
- & Andrew S. Protheroe
-
Article
| Open AccessManual lymphatic drainage adds no further volume reduction to Complete Decongestive Therapy on breast cancer-related lymphoedema: a multicentre, randomised, single-blind trial
- Mette Tambour
- , Marianne Holt
- & Bibi Gram
-
Article
| Open AccessEfficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
- Simon Pernot
- , Olivier Dubreuil
- & Julien Taieb
-
Article
| Open AccessSociodemographic variation in the use of chemotherapy and radiotherapy in patients with stage IV lung, oesophageal, stomach and pancreatic cancer: evidence from population-based data in England during 2013–2014
- Katherine E Henson
- , Anna Fry
- & Sean McPhail
-
Clinical Study
| Open AccessImpact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study
- Leigh G Seamon
- , James J Java
- & Krishnansu S Tewari
-
Epidemiology
| Open AccessTetracycline use and risk of incident skin cancer: a prospective study
- Wen-Qing Li
- , Aaron M Drucker
- & Abrar A Qureshi
-
Translational Therapeutics
| Open AccessEx vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
- Peder R Braadland
- , Guro Giskeødegård
- & May-Britt Tessem
-
Letter to the Editor
| Open AccessComment on ‘Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion’
- Teh-Ia Huo
- , Po-Hong Liu
- & Chia-Yang Hsu
-
Clinical Study
| Open AccessLong-term outcomes of patients with 10 or more colorectal liver metastases
- M A Allard
- , R Adam
- & J Figueras
-
Genetics and Genomics
| Open AccessWhole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma
- Hiroaki Itamochi
- , Tetsuro Oishi
- & Toru Sugiyama
-
Editorial |
Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
- N LeVasseur
- & S K Chia
-
Translational Therapeutics
| Open AccessHuman equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
- Bruno Vincenzi
- , Silvia Stacchiotti
- & Giuseppe Tonini
-
Clinical Study
| Open AccessPhase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
- Richard Kim
- , E Gabriela Chiorean
- & David Portnoy
-
Clinical Study
| Open AccessA phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
- Glen J Weiss
- , Jordan Waypa
- & Vivek Khemka
-
Clinical Study
| Open AccessThe influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival
- Marissa C van Maaren
- , Reini W Bretveld
- & Sabine Siesling
-
Short Communication
| Open AccessOncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice
- Miika Martikainen
- , Janne Ruotsalainen
- & Ari Hinkkanen
-
Molecular Diagnostics
| Open AccessHuman papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer
- Steffen Wagner
- , Claus Wittekindt
- & Jens Peter Klussmann
-
Clinical Study
| Open AccessEfficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
- Luca Triggiani
- , Filippo Alongi
- & Stefano Maria Magrini
-
Clinical Study
| Open AccessThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
- Rachna T Shroff
- , Mark Yarchoan
- & Nilofer S Azad
-
Translational Therapeutics
| Open AccessPretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
- Didier Meulendijks
- , Linda M Henricks
- & Jan H M Schellens
-
Translational Therapeutics
| Open AccessDifferential pattern of HIF-1α expression in HNSCC cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect
- Anne-Sophie Wozny
- , Alexandra Lauret
- & Claire Rodriguez-Lafrasse
-
Translational Therapeutics
| Open AccessLithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
- Sheng Han
- , Lingxuan Meng
- & Anhua Wu
-
Epidemiology
| Open AccessAcid-suppressing therapies and subsite-specific risk of stomach cancer
- E Christina M Wennerström
- , Jacob Simonsen
- & Charles S Rabkin
-
Letter to the Editor
| Open AccessReply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
- Samantha Bowyer
- , Prashanth Prithviraj
- & Oliver Klein
-
Letter to the Editor
| Open AccessComment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’
- Uffe Ravnskov
-
Clinical Study
| Open AccessCombination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial
- Roberto Pili
- , Glenn Liu
- & Michael A Carducci
-
Clinical Study
| Open AccessA phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
- Richard H Wilson
- , TR Jeffry Evans
- & Ruth Plummer
-
Translational Therapeutics
| Open AccessMT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib
- Cassandre Yip
- , Pierre Foidart
- & Agnès Noël
-
Translational Therapeutics
| Open AccessA combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
- L M Schiffmann
- , M Brunold
- & O Coutelle
-
Molecular Diagnostics
| Open AccessThe predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)
- Ananya Choudhury
- , Catharine M West
- & Nicholas James
-
Clinical Study
| Open AccessChemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
- Kristina Lindemann
- , Emma Gibbs
- & Gunnar Kristensen
-
Clinical Study
| Open AccessPhase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
- Adil Daud
- , Harriet M Kluger
- & Geoffrey I Shapiro
-
Translational Therapeutics
| Open AccessMathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
- C Faivre
- , R El Cheikh
- & F Barlesi
Browse broader subjects
Browse narrower subjects
- Adverse effects
- Biological therapy
- Bisphosphonates
- Cardiac device therapy
- Drug therapy
- Gene therapy
- Hormonal therapies
- Immunotherapy
- Interventional cardiology
- Nutrition therapy
- Pain management
- Palliative care
- Placebo effect
- Radiotherapy
- Rehabilitation
- Renal replacement therapy
- Reproductive techniques
- Stem-cell therapies
- Surgery
- Therapeutic endoscopy